Fresh tri­al da­ta for­ti­fy po­si­tion of Roche's oral ther­a­py in spinal mus­cu­lar at­ro­phy bat­tle­ground

With an FDA de­ci­sion date loom­ing, Roche on Wednes­day un­veiled pos­i­tive piv­otal da­ta on its block­buster-bound oral spinal mus­cu­lar at­ro­phy (SMA) drug in pa­tients with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER